The FDA has issued an updated draft guidance on the naming of biologics, biosimilars, and interchangeable biosimilars.
The FDA no longer intends to retroactively give approved biologics 4-letter suffixes devoid of meaning, according to an updated draft guidance on the naming of biologics, biosimilars, and interchangeable biosimilars.
However, the new guidance explains that the agency will continue to assign suffixes to newly approved innovator biologics, biosimilars, or interchangeable biosimilars. In addition, FDA does not intend to add suffixes to the names of transition products such as insulins, and once interchangeable biosimilars become a reality, the FDA will designate a proper name comprising the core name and a suffix. Any product first approved as a biosimilar and later determined to be interchangeable with its reference will keep its original nonproprietary name, inclusive of the suffix.
Additionally, the FDA is implementing an internal procedure for FDA staff to ensure consistency and transparency in the review process for suffixes, and it is considering whether it will extend its naming convention to vaccines.
In a statement, outgoing FDA Commissioner Scott Gottlieb, MD, acknowledged that there is considerable ongoing debate over the naming of biologics and biosimilars in the United States, particularly with respect to 4-letter suffixes that some stakeholders have deemed to be a hindrance to building confidence in biosimilars. In fact, other regulatory territories, such as Canada, have expressly opted for suffix-free naming conventions.
Gottlieb recognized in his comments that some stakeholders have called on the FDA to forego these suffixes in the interest of promoting biosimilar adoption. However, he said, “I do not believe that the naming convention should be used to advance these goals if it could come at the expense of the ability to ensure patient safety. Nor do I believe the inclusion of a suffix will frustrate the broader aim of inspiring strong biosimilar competition.”
According to the FDA, the naming convention will allow the agency to effectively monitor all biologics to promote patient safety. “Even though biosimilars have no clinically meaningful differences from the reference product, these unique suffixes are a critical component of the FDA’s ability to track adverse events to a specific biological product and manufacturer so that appropriate action can be taken when needed to protect patients,” said Gottlieb. He added that, over time, patients and providers will increasingly understand that suffixes reflect a consistent naming convention, and that they are not a signal of inferior product quality.
As for the agency’s decision not to append suffixes to the names of already approved biologics, he noted that undertaking a name change would be costly. If costs were passed to patients, such an outcome would be contrary to the aims of the biosimilars program, which seeks to make biologic treatment less expensive for patients and the healthcare system.
The FDA will receive comments on the draft guidance over the next 60 days with a view toward issuing a final version of the guidance in the future.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.